Search results
May 8, 2024 · London, 8 May 2024 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, has launched Midazolam Injection, USP, in 2mg/2mL and 10mg/2mL doses. The product has been launched in the US in a prefilled syringe form and is indicated for: intramuscularly or intravenously for preoperative sedation/anxiolysis/amnesia;
- Home
Hikma has strong start to 2024, with continued momentum...
- About
Hikma enters the Spanish generic injectables market,...
- Products
We manufacture and bring patients across North America, MENA...
- Investors
Hikma enters the Spanish generic injectables market,...
- Newsroom
Newsroom - Hikma launches Midazolam Injection, USP, in a...
- Results, Reports and Presentations
Investors. Learn more about our proven track record of value...
- Calendar
Investors. Learn more about our proven track record of value...
- Shareholder Information
Shareholder Information - Hikma launches Midazolam...
- Financial Information
Financial Information - Hikma launches Midazolam Injection,...
- Home
6 days ago · Stock analysis for Hikma Pharmaceuticals PLC (HIK:London) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
- 8.8K
May 21, 2024 · Hikma Pharmaceuticals PLC specializes in developing, producing, and selling drugs used in treating cardiovascular diseases, infections, cancers, diabetes, etc. Net sales break down by family of products as follows: - generic injectable products (45.3%); - brand name drugs (27.5%); - generic products taken orally (26.7%); - other (0.5%).
- (11)
- HIKMA PHARMACEUTICALS PLC
5 days ago · About Hikma Pharmaceuticals. Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.
5 days ago · Latest Hikma Pharmaceuticals PLC (HIK:LSE) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more.
- 1,750.00
- 1,763.00
- 1,807.00
- 1,786.00
People also ask
What is Hikma 503B?
Who is Hikma Pharmaceuticals plc?
What is Hikma branded business segment?
Did Hikma Pharmaceuticals buy Boehringer Ingelheim?
3 days ago · Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. Show more.
May 20, 2024 · A high-level overview of Hikma Pharmaceuticals PLC (HKMPF) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.